



**HAL**  
open science

## MELAS can be psychiatric and neurological

Josef Finsterer, Sinda Zarrouk-Mahjoub

► **To cite this version:**

Josef Finsterer, Sinda Zarrouk-Mahjoub. MELAS can be psychiatric and neurological. *eNeurologicalSci*, 2018, 11, pp.3-4. 10.1016/j.ensci.2018.04.002 . pasteur-02017684

**HAL Id: pasteur-02017684**

**<https://riip.hal.science/pasteur-02017684>**


Submitted on 13 Feb 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License



## Letter to the editor

## MELAS can be psychiatric and neurological



## ARTICLE INFO

## Keywords:

Mitochondrial  
mtDNA  
Phenotype  
Genotype  
MELAS  
Stroke-like episode  
Epilepsy

## Letter to the Editor

We read with interest the article by Ge et al. about a 37 years old female with MELAS syndrome due to the m.3243A > G variant, manifesting with short stature, hearing impairment, psychiatric disease (agitation, acoustic hallucinations), hypothyroidism, apraxia, alexia, epilepsy, migraine, arterial hypotension, lactic acidosis, and a stroke-like episode (SLE) [1]. We have the following comments and concerns.

We should be informed which of the clinical abnormalities were transient and attributable to the SLE and which remained part of the long-term phenotype. It is conceivable that manifestations of the SLE included seizures, the psychiatric abnormalities, apraxia, and alexia. Additional features, which may be attributable to a SLE include hemianopia, muscle weakness, aphasia, cognitive impairment, and psychosis [2]. Which of these additional features were present in the presented patient? We would also like to know if SLE manifestations completely resolved and after which time the status quo ante was reached. Occasionally, different SLEs overlap or follow consecutively each other [3].

It is reported that the SLE showed up on MRI as hyperintensity on DWI and as hypointensity on ADC, thus suggesting a cytotoxic edema. Cytotoxic edema is characteristic for ischemic stroke. Thus, we should be informed by which means an ischemic stroke was excluded in the presented case. Which was the cardiovascular risk profile of this patient? MELAS may be also associated with cardiac disease, including systolic dysfunction and atrial fibrillation, diabetes, and hyperlipidemia [4,5]. Did the patient present with atrial fibrillation, systolic dysfunction, noncompaction, diabetes, nicotine smoking, or hyperlipidaemia? Were carotid ultrasound or angiography of the extra-cerebral arteries normal?

Cerebro-spinal fluid (CSF) investigations were normal but it is not mentioned if CSF lactate was determined [1]. According to the MR-spectroscopy there was lactate elevation in the CSF [1]. Was CSF lactic acidosis confirmed by direct determination of the lactate in the CSF?

Did the patient receive L-arginine orally or intravenously and which dosage was applied during the acute respectively chronic stage of the SLE? Particularly during the acute stage of the SLE intravenous L-arginine should be applied, unless there are any contraindications against administering this agent.

Obviously, the patient received phenobarbital as an antiepileptic drug without detailing the dosage and the duration of the application [1]. From phenobarbital it is well known that it is mitochondrion-toxic [6]. Did the phenotype deteriorate after administration of phenobarbital? Were also other antiepileptic drugs applied?

We do not agree with the statement that thyroid dysfunction is rare in MELAS/MIDs. Thyroid dysfunction is one of the dominant clinical manifestations of MELAS [7] and frequently not attributed the underlying metabolic disease. However, endocrine disease in general is a prominent phenotypic feature of MELAS and mitochondrial disorders in general, why presence of thyroid dysfunction should always raise the suspicion of an underlying mitochondrial defect.

mtDNA mutations are usually present in the heteroplasmic form in mitochondrial disorders. Which were the heteroplasmy rates in blood and parenchymatous organs, such as liver, kidneys, or the myocardium. Was there a difference between the heteroplasmy rates of the saliva, fibroblasts, muscle, blood lymphocytes, or the urothelial cells?

mtDNA mutations are maternally transmitted in two thirds of the cases [8]. We should be informed if the patient's family history was positive for a mitochondrial defect in first-degree relatives, and if the mutation was also found in other clinically or subclinically affected members of the family?

Overall, this interesting case could be more meaningful if the family history would have been provided, if genetic studies would have been extended to first-degree family members, if heteroplasmy rates of the m.3243A > G variant would have been provided in various tissues, if the multisystem natures of MELAS would have been addressed, and if organs/tissues not obviously affected, would have been investigated prospectively.

## Conflicts of interest

There are no conflicts of interest.

## Funding

No funding was received.

<https://doi.org/10.1016/j.ensci.2018.04.002>

Received 22 December 2017; Accepted 10 April 2018

Available online 13 April 2018

2405-6502/ © 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Author contribution**

JF: design, literature search, discussion, first draft, SZ-M: literature search, discussion, critical comments.

**References**

- [1] Y.X. Ge, B. Shang, W.Z. Chen, et al., Adult-onset of mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome with hypothyroidism and psychiatric disorders, *eNeurol. Sci.* 6 (2016 Nov 4) 16–20.
- [2] A.W. El-Hattab, A.M. Adesina, J. Jones, et al., MELAS syndrome: clinical manifestations, pathogenesis, and treatment options, *Mol. Genet. Metab.* 116 (2015) 4–12.
- [3] H.S. Kim, D.I. Kim, B.I. Lee, et al., Diffusion-weighted image and MR spectroscopic analysis of a case of MELAS with repeated attacks, *Yonsei Med. J.* 42 (2001) 128–133.
- [4] E. Malfatti, P. Laforêt, C. Jardel, et al., High risk of severe cardiac adverse events in patients with mitochondrial m.3243A > G mutation, *Neurology* 80 (2013) 100–105.
- [5] W. Li, W. Zhang, F. Li, et al., Mitochondrial genetic analysis in a Chinese family suffering from both mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes and diabetes, *Int. J. Clin. Exp. Pathol.* 8 (2015) 7022–7027.
- [6] J. Finsterer, Toxicity of antiepileptic drugs to mitochondria, *Handb. Exp. Pharmacol.* 240 (2017) 473–488.
- [7] P. Balestri, S. Grosso, Endocrine disorders in two sisters affected by MELAS syndrome, *J. Child. Neurol.* 15 (2000) 755–758.
- [8] J. Poulton, J. Finsterer, P. Yu-Wai-Man, Genetic counselling for maternally inherited mitochondrial disorders, *Mol. Diagn. Ther.* 21 (2017) 419–429.

Josef Finsterer<sup>a,\*,1</sup>, Sinda Zarrouk-Mahjoub<sup>b,1</sup>

<sup>a</sup> *Krankenanstalt Rudolfstiftung, Vienna, Austria*

<sup>b</sup> *University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunisia*

*E-mail address: fifigs1@yahoo.de*

\* Corresponding author at: Postfach 20, 1180 Vienna, Austria.

<sup>1</sup> Both authors contributed equally.